In an interview in the spring of 2015, Damiano confidently predicted: «We're going to be running a pivotal trial by the end of the year,» referring to the type of
clinical trial designed specifically to meet the FDA's standards for getting a device approved.
Designed to block the newly identified mechanism of PARP1 activation, these new inhibitors will
specifically target PARP1, in contrast to the PARP1 inhibitors currently being tested in
clinical trials.